Related Experiment Video

Updated: Jun 27, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

[Pneumocystis pneumonia]

Takeshi Fujii1

  • 1Department of Infectious Diseases and Applied Immunology, The University of Tokyo, The Institute of Medical Science.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|December 17, 2008
PubMed

Insights

Pneumocystis jirovecii causes lung infections in immunocompromised individuals, including those with HIV and cancer. Despite immune defects, diabetes does not significantly increase Pneumocystis pneumonia risk.

Area of Science:

  • Mycology: Classification of Pneumocystis jirovecii as an ascomycetous fungus.
  • Immunology: Focus on cell-mediated immunity defects in various patient groups.

Context:

  • Pneumocystis jirovecii (formerly Pneumocystis carinii) is an opportunistic pathogen.
  • Infections occur primarily in immunocompromised patients, including those with HIV, malignancies, and transplant recipients on immunosuppressants.

Purpose:

  • To review the biology of Pneumocystis jirovecii.
  • To describe the pathogenesis of Pneumocystis pneumonia (PCP).
  • To summarize clinical, laboratory, and radiological findings of PCP in immunocompromised hosts.

Summary:

  • Pneumocystis jirovecii causes opportunistic pulmonary infections in immunocompromised individuals.
  • Diabetes mellitus, despite associated immune defects, is not a significant risk factor for PCP.
  • The review covers pathogen biology, host lung damage, and diagnostic findings of PCP.

Impact:

  • Provides a comprehensive overview of Pneumocystis pneumonia for clinicians and researchers.
  • Highlights the importance of identifying immunocompromised states for PCP diagnosis.
  • Clarifies the role of diabetes in the context of Pneumocystis pneumonia risk.

More Related Videos

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases03:22

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Published on: March 1, 2024

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...